Pharma Companies Have Increased MRP By 20-50 Per Cent Over The Past Six Months

Palanpur:  A sudden surge in the prices of life-saving drugs has left consumers reeling, as pharma companies have increased costs by 20-50 per cent over the past six months. Essential medications for hypertension, diabetes, cancer and common gastrointestinal ailments have reached new price highs, while the cost of antibiotics used in surgeries has nearly doubled.

Despite the applicability of the Essential Commodities Price Control Act in the state — which grants district magistrates authority to regulate and take action against price violations — there appears to be no enforcement against the profiteering of pharmaceutical companies.

Social activist Subhash Sharma highlighted shocking discrepancies in drug pricing. For instance, Pantoprazole-40 mg, prescribed for acidity, has an MRP of Rs 130 for a strip of 10 tablets, while its actual cost price is just Rs 20. This exposes profit margins exceeding 90 per cent, with some medications reportedly yielding profits of 1,000 per cent to 1,500 per cent for retailers. “This is only one example,” Sharma said, pointing out that similar price gouging affects hundreds of

In the absence of stringent checks, companies print exorbitant maximum retail prices (MRPs) on generic medicines, forcing poor patients to pay unjustified amounts. Many accuse administrative bodies and vigilance agencies of turning a blind eye, enabling pharmaceutical companies to exploit consumers.

A senior official from the state Drug Control Department admitted that state authorities have limited powers in this matter. “The Government of India has allowed pharma companies to print MRPs on all drugs, and only the Central Drug Controller can intervene,” the official stated.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit